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LETTER TO THE EDITOR
Impact of assumptions – the example of the Welch-analysis of mammography
screening effectiveness
Elsebeth Lynge, Anna-Belle Beau and Søren Lophaven
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
Introduction
Based on analysis of SEER data from 1975 to 2012, Welch
et al. [1] concluded that in screening, women were more
likely to have breast cancer detected ‘that was overdiag-
nosed than to have earlier detection of a tumor that was
destined to become large’, and that ‘the reduction in breast
cancer mortality after the implementation of screening was
predominantly the result of improved systemic therapy.’
Welch assumptions
The Welch et al. analysis builds on a number of assumptions
that might not be unproblematic.
First, it was assumed ‘that the underlying probability that
clinically meaningful breast cancer would develop was stable’
over time given no screening. This assumption was based on
the observed, very low and stable incidence of metastatic
breast cancer. As the breast cancer incidence data analyzed
by Welch et al. started in 1975 and screening in the USA dis-
seminated shortly thereafter, limited data were available
from a prescreening period. However, long-term breast can-
cer incidence data from Rochester, Minnesota [2], from Kaiser
Permanente, Portland [3], and from the Connecticut Tumor
Registry [4], showed prescreening, cohort-related increases in
the breast cancer incidence. Based on long-term prescreen-
ing breast cancer incidence data from other countries (for
instance Denmark, see section below), it seems likely that the
US prescreening cohort trends would have continued also
after the start of screening.
Second, screening implies a change in time of diagnosis
and therefore a change in the incidence pattern. At the start
of screening, a prevalence peak is observed, during screening
an artificial aging, and when the women have exited screen-
ing a compensatory dip will be seen in the incidence [5]. If it
takes 2 years to carry out the prevalence screen, around a
100% increase in incidence will be observed during the
period [6]. Screening started gradually in the USA, with 17%
(aged 50þ) in 1978 having had a mammogram to 74% in
1992 (aged 40þ) [7]. This means that in the USA, the preva-
lence peak is spread out over a long time interval, and that
very long time will pass before the compensatory dip
becomes visible at the population level. It is therefore ques-
tionable when Welch et al. attribute the observed increase in
breast cancer incidence to overdiagnosis. The use of
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calendar-specific, age-standardized breast cancer incidence
rates for all women aged 40þ is simple a too crude tool to
identify the dynamic of the incidence rates during screening.
Third, Welch et al. estimated the impact of screening on
breast cancer mortality by combining stage-specific incidence
and case fatality rates, and concluded that ‘improved treat-
ment was responsible for at least two-third … of the reduc-
tion in breast cancer mortality’. However, this calculation is
still based on the questionable assumption ‘that the underly-
ing probability that clinically meaningful breast cancer would
develop was stable’ over time given no screening.
Breast cancer incidence in Denmark
In Denmark, nationwide registration based on international
coding schemes started for incident cancer cases in 1943,
and for causes of death in 1951. The age-standardized (2000
Nordic population) breast cancer incidence for women age
40 years and above increased steadily over time, while the
breast cancer mortality was stable up until the mid-1990,
thereafter it decreased [8] (Figure 1).
In 1951–1952, a breast self-examination campaign took
place in Denmark [9]. In modeling of lymph node status data
from 1978 to 1994, the overall increase in breast cancer inci-
dence derived from node-negative and moderately node-
positive tumors, indicating increased breast cancer awareness
[10]. Population-based screening was implemented step-wise
in Denmark, though always targeting only women aged
50–69 years, and screening outside the organized programs
was rare [11]. The first regional program started in
Copenhagen in 1991 and targeted about 8% of women [12],
the next regional programs started around 1994, targeting
about 11% of women [13], and a very small regional program
started in 2001. In 2001–2002, also high-frequency ultrasound
devices and stereotactic breast biopsies were implemented
which increased the screen-detection rate [14]. National roll-
out of screening took place in 2008–2010 [15].
The breast self-examination campaign and the start of
the screening programs left marks on the time trend in
breast cancer incidence in Denmark. But in the long-time
perspective, these marks appeared as irregularities on an
underlying increasing trend. In the years before screening,
the increase in incidence seems to have come primarily
from node-negative and moderately node-positive tumors.
As improved awareness – like screening – will move the
time of diagnosis forward, it can have some temporary
impact on the time trend in the incidence. Some may
interpret an increase in node-negative tumors as an indi-
cator of overdiagnosis of indolent tumors. But women will
not harbor an inexhaustible pool of indolent tumors.
Overdiagnosis is therefore unlikely to explain the doubling
of the breast cancer incidence over the past 60 years in
Denmark.
Conclusions
Welch et al. presented an interesting and novel approach to
assess the effect of breast cancer screening. However, the
opportunistic and gradual implementation of screening in
the USA makes it very difficult to separate out a possible
screening effect from the underlying time trends and
improvement in treatment.
In this respect, data from countries with population-based,
organized screening programs are more useful. This is
Figure 1. Age-standardized (2000 Nordic population) breast cancer incidence (red) and mortality (green) for women 40þ years in Denmark 1943–2014.
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especially the case, if the screening program has been imple-
mented region-wise, because it is then possible to identify a
comparison group not yet invited to screening. However,
screening changes the age-specific incidence in cohorts of
women offered screening. This includes a prevalence peak at
first screen; an artificial aging at subsequent screens; and a
compensatory dip after end of screening [5,6]. Therefore,
studies of overdiagnosis require also that women can be fol-
lowed for a sufficiently long period after end of screening for
the compensatory dip to materialize. Such studies have been
undertaken in for instance Florence Italy [16]; in Finland [17];
and in Denmark [18].
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A case of isolated small cell carcinoma of the brain
C. Noonana and M. Jamesa,b
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Case description
Presentation
A 43-year-old Caucasian female presented to the emergency
department with a four week history of decreased fluency of
speech and headache. She had no significant previous med-
ical history or regular medications, although was a current
cigarette smoker with 20 pack-year history. On examination,
she had expressive dysphasia, global right-sided hypoesthe-
sia, hypertonicity and weakness of the right upper limb.
Investigation
Her initial MR brain revealed prominent rim-enhancing neo-
plasms to the left parietal (41mm AP 35mm T) and poster-
omedial temporal lobes (25mm AP 11mm T) with
associated mass effect (as shown in Figure 1). A provisional
diagnosis of brain metastases from an unknown primary was
made. Staging investigations (including CT, MR and FDG PET-
CT modalities) showed no evidence of extra-cranial disease.
Serum haematology, biochemistry and tumour markers
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